View Post

Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour From: onclive.com Given the number of prophylactic interventions that are now available, counseling patients with early-stage HER2-positive breast cancer on the benefit of extended adjuvant therapy with neratinib (Nerlynx) or considering its use in those with central nervous system metastases could be beneficial, said Michel Velez, MD. “We know that neratinib has value in the extended adjuvant …